Resumo

POUBEL, Victor Lousan do Nascimento et al. Maxillomandibular osteonecrosis induced by bisphosphonate: a literature review. Rev. cir. traumatol. buco-maxilo-fac. [online]. 2012, vol.12, n.1, pp. 33-42. ISSN 1808-5210.

The need for new pharmaceutical technologies in the treatment of several types of malignant lesions led to the emergence of the bisphosphonates, a drug widely administered to patients with breast and prostate cancer with bone metastases, multiple myeloma, osteoporosis, Paget's disease, hypercalcemia and other malignant metastatic bone lesions. Several adverse reactions have emerged, in particular osteonecrosis of the jaw (ONJ). This paper sets out to objectively address some of the main characteristics of this drug, its complications and role in the prevention and treatment of ONJ. Given the absence of a protocol for the effective treatment of ONJ, prevention is seen to be the best option. It is important to note that patients undergoing chemotherapy with bisphosphonates should be referred to a dental unit for careful evaluation of possible predisposing factors. Apart from the inherent difficulty of the treatment of patients with biphosphonate-associated maxillomandibular osteonecrosis, its results are unpredictable.

Palavras-chave : Bisphosphonates; Osteonecrosis; Mandible; Prevention.